Seed Amplification Assays for Parkinson's Disease: A Review of α‐Synuclein Assays in Body Fluids and Tissues
Journal of Neurochemistry · 2026
DOI: 10.1111/jnc.70435 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Neurochemistry, 2026. Verfasst von Weijie Kong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, Unit of Medical and Dental Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. Hauptthemen laut MEDLINE: alpha-Synuclein, Parkinson Disease, Body Fluids. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, JSPS Grants-in-Aid for Scientific Research.
Abstract (Originalsprache)
The pathological core of Parkinson's disease and related synucleinopathies involves the misfolding and aggregation of α‐synuclein. Seed amplification assays (SAAs) have revolutionized the detection of pathological α‐synuclein by enabling highly sensitive and specific identification of seeding activity. Cerebrospinal fluid (CSF)‐based real‐time quaking‐induced conversion (RT‐QuIC) demonstrates exceptional diagnostic accuracy for sporadic Parkinson's disease (PD) and dementia with Lewy bodies (DLB), with sensitivity reaching 93.3%–94.6% and pooled specificity of 94% (95% CI: 0.92–0.96), consistent with the meta‐analysis of 21 core CSF studies. Alternative samples such as skin and intestinal tissues offer diagnostic accuracy up to 94.1%, providing less invasive options. These assays can distinguish conformational differences between Parkinson's disease/Lewy body dementia and multiple system atrophy (MSA), revealing potential for differential diagnosis through strain typing. In prodromal screening, SAAs show remarkable utility, with positivity rates exceeding 80% in idiopathic rapid eye movement sleep behavior disorder (iRBD) cohorts, indicating detection years before clinical diagnosis. Despite these advances, current limitations include small‐sample sizes in many studies, insufficient multicenter validation, and lack of standardized protocols affecting interlaboratory consistency. Future efforts should focus on establishing standardized procedures, integrating digital biomarkers, and validating these technologies across diverse populations and disease stages to facilitate widespread clinical implementation. This study systematically evaluates the diagnostic performance of α‐synuclein SAAs across biological samples, their role in differential diagnosis, and their potential in prodromal prediction and disease monitoring. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Sciences, Unit of Medical and Dental Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
- Division of Neurology and Gerontology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Iwate, Japan.
- Department of Neurology and Stroke, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan.
ORCID-Profile: Tetsuya Maeda, Atsushi Iwata
Förderung
- Japan Agency for Medical Research and Development
- JSPS Grants-in-Aid for Scientific Research
Zitieren
APA
Kong, W., Satoh, K., Shimamura, M. I., Maeda, T., Takahashi, K., Kurihara, M., & Iwata, A. (2026). Seed Amplification Assays for Parkinson's Disease: A Review of α‐Synuclein Assays in Body Fluids and Tissues. Journal of Neurochemistry. https://doi.org/10.1111/jnc.70435
Vancouver
Kong W, Satoh K, Shimamura MI, Maeda T, Takahashi K, Kurihara M, et al. Seed Amplification Assays for Parkinson's Disease: A Review of α‐Synuclein Assays in Body Fluids and Tissues. Journal of Neurochemistry. 2026. doi:10.1111/jnc.70435
BibTeX
@article{Kong2026,
author = {Kong, Weijie and Satoh, Katsuya and Shimamura, Mika Inada and Maeda, Tetsuya and Takahashi, Kenta and Kurihara, Masanori and Iwata, Atsushi},
title = {Seed Amplification Assays for Parkinson's Disease: A Review of α‐Synuclein Assays in Body Fluids and Tissues},
journal = {Journal of Neurochemistry},
year = {2026},
doi = {10.1111/jnc.70435}
}
EUVIMED